Background: Radical cystectomy and bilateral pelvic lymphadenectomy is considered the treatment of choice for patients with muscle invasive transitional cell bladder cancer. Following radical cystectomy the surgeon would choose an appropriate modality of urinary diversion from a plethora of methods. Radical cystectomy with any type of diversion remains a complication-prone surgery. This study aims at reviewing the peri-operative challenges and morbidities experienced with radical cystectomy and W-ileal pouch urinary diversion in a tertiary hospital in Nigeria.
Aims & Objective: To report experience with radical cystectomy and W-ileal pouch construction in patients with muscle invasive transitional cell urinary bladder carcinoma.
Patients & Methods: The case notes of patients diagnosed with muscle invasive transitional cell bladder carcinoma (T2/3NoMo) who underwent radical cystectomy and W-ileal pouch construction from December 2006 to December 2011 at the Jos University Teaching Hospital, Jos, Nigeria were retrospectively studied. Patients were evaluated for age, sex, duration of surgery, estimated blood loss, duration of hospital stay, and complications after surgery.
Results: Six patients had their records reviewed. Mean age was 55.8 years (range 32 - 66years). Male to female ratio was 5:1. Mean hospital stay was 31 days, with all of the patients requiring intensive care for a mean of 24 hours (range 24-72 hours). Mean hospital stay was 31 days (range 21-40 days). Mean estimated blood loss was 891 ml (range 720-1500ml). Mean duration of surgery was 10.3 hours (range 8-12 hours). Commonest complication was urine retention secondary to mucus plug in 50%. Operative mortality was 16.7%.
Conclusion: Radical cystectomy and W-ileal pouch construction due to its technical complexity and challenging postoperative management necessitates a team approach with experienced surgeons, anesthetists, intensivists and stoma care specialist, among others.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170286 | PMC |
Eur Urol
March 2025
Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
Cancer Rep (Hoboken)
March 2025
CUROS Urologisches Zentrum, Cologne, Germany.
Introduction: Transurethral resection of the bladder (TURB) is a common urological procedure, typically performed in an inpatient setting. This study aims to investigate safety, quality, and patient satisfaction aspects of TURB in an outpatient setting, reflecting the emerging strategy of outpatientization of surgical procedures in the German healthcare system.
Methods: We retrospectively analyzed a cohort of 100 patients who underwent outpatient TURB.
Can Vet J
March 2025
Veterinary Medical Center (Takahashi, Motegi, Fujita, Hashimoto) and Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences (Kato, Nakagawa, Nishimura) and Laboratory of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences (Maeda), The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
Objective: This study aimed to evaluate outcomes and complications in dogs with urothelial carcinoma (UC) of the bladder trigone treated with total cystectomy using uretero-prepuce/vagina/cutaneous anastomosis combined with medical treatment.
Animals: Twenty-one dogs.
Procedure: Total cystectomy was completed as follows: The whole bladder and urethra were removed, and the ureters were anastomosed to the skin in 1 case and to the vagina in 9 cases in females.
Clin Genitourin Cancer
February 2025
Department of Urology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address:
Introduction: Treatment patterns for patients with bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy (RC) are inconsistently reported. We retrospectively described demographic, clinical, and treatment characteristics for these patients and assessed their clinical outcomes.
Patients And Methods: Medical charts of patients with BCG-unresponsive high-risk NMIBC (carcinoma in situ [cohort A] or T1/high-grade Ta [cohort B]) who were ineligible for or declined RC documented between January 1, 2011, and December 31, 2018, at 15 academic centers were reviewed.
Urol Pract
March 2025
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!